Sun Pharmaceutical Industries has informed that a meeting of the Board of Directors of the company is scheduled to be held on Monday, May 30, 2022: To approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2022 and to recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2022 subject to approval of the shareholders at the ensuing Annual General Meeting. Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the trading window for trading in Company's shares by Designated Persons has been closed from April 01, 2022 till June 01, 2022 after 48 hours of the declaration of financial results. This intimation is being made pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.45 |
| Dr. Reddys Lab | 1237.15 |
| Cipla | 1237.30 |
| Zydus Lifesciences | 943.05 |
| Lupin | 2332.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: